The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups.

Hongjuan ZhengChenyang GeHaiping LinShishi ZhouWanfen TangQinghua WangXia ZhangXiayun JinXifeng XuJinlin DuJianfei Fu

Published in: PloS one (2023)

Young age could predict worse BCSD of patient with stage I-III and HoR+/HER2- breast cancer. The escalating therapy was recommended to young age breast cancer with stage I-III and HoR+/HER2- subtype.

Keyphrases

middle aged
case report
stem cells
metabolic syndrome
bone marrow
young adults
skeletal muscle
cell therapy
childhood cancer